# US 2019/0314444 A1 · Etbr antagonist compounds, compositions, and uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314444 A1
- Document ID: US20190314444A1
- Status: Published application
- Kind: A1
- Application number: 16/419,931
- Filed: 2019-05-22
- Published: 2019-10-17
- Earliest claimed: 2018-03-30
- Assignees: ENB Therapeutics, Inc.
- Applicants: ENB Therapeutics, Inc.
- Inventors: Sumayah JAMAL
- Web page: https://patentgrep.com/patent/US20190314444A1

## CPC

- A61K 38/06: Tripeptides
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 5/06017: {and aliphatic}
- C07K 5/06078: {and aromatic or cycloaliphatic}
- C07K 5/06139: {with the first amino acid being heterocyclic}
- C07K 5/0804: {and aliphatic}
- C07K 5/0808: {the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu}
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein are ETBR antagonist compounds, pharmaceutical compositions thereof, methods for treating cancers, and methods of forming tertiary lymphoid organs.

## Claims

### Claim at position 1

-70. (canceled)

### Claim 71

A method of forming a tertiary lymphoid organ (TLO) in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising an ETBR antagonist and a pharmaceutically acceptable excipient.

### Claim 72 (depends on 71)

The method of claim 71, wherein the ETBR antagonist is BQ-788, A192621, A-308165, IRL-1038, IRL-2500, RO-468443, BQ-017, or an analog thereof.

### Claim 73 (depends on 71)

The method of claim 71, wherein the ETBR antagonist is BQ-788.

### Claim 74 (depends on 71)

The method of claim 71, wherein the ETBR antagonist is in a nanoparticle formulation.

### Claim 75 (depends on 71)

The method of claim 71, wherein the subject has a cancer.

### Claim 76 (depends on 75)

The method of claim 75, wherein the tertiary lymphoid organ is formed at a site of the cancer or in a peripheral tissue adjacent to a site of the cancer.

### Claim 77 (depends on 75)

The method of claim 75, wherein the cancer is a solid tumor.

### Claim 78 (depends on 75)

The method of claim 75, wherein the cancer is a melanoma, malignant squamous cell carcinoma, metastatic squamous cell carcinoma, glioblastoma, brain cancer, pancreatic cancer, colon cancer, breast cancer, ovarian cancer, prostate cancer, or any combination thereof.

### Claim 79 (depends on 71)

The method of claim 71, wherein the pharmaceutically acceptable excipient is dimethyl sulfoxide (DMSO), LYOCELL (reversed cubic phase liquid crystal dispersion), soybean oil, INTRAVAIL (transmucosal absorption enhancement agents), PROTEK (protein stabilization excipients), hydrogel, or any combination thereof.

### Claim 80 (depends on 71)

The method of claim 71, further comprising administering to the subject an immune checkpoint inhibitor.

### Claim 81 (depends on 80)

The method of claim 80, wherein the immune checkpoint inhibitor is an anti-PD1 agent, an anti-PD-L1 agent, an anti-CTLA4 agent, or any combination thereof.

### Claim 82 (depends on 80)

The method of claim 80, wherein the immune checkpoint inhibitor is an anti-PD1 antibody.

### Claim 83 (depends on 82)

The method of claim 82, wherein the anti-PD1 antibody is pembrolizumab, pidilizumab, BMS-936559, nivolumab, or any combination thereof.

### Claim 84 (depends on 83)

The method of claim 83, wherein the anti-PD1 antibody is the pembrolizumab.

### Claim 85 (depends on 80)

The method of claim 80, wherein the ETBR antagonist is BQ-788, and wherein the immune checkpoint inhibitor is pembrolizumab.

### Claim 86 (depends on 80)

The method of claim 80, wherein the ETBR antagonist and the immune checkpoint inhibitor are administered simultaneously.

### Claim 87 (depends on 80)

The method of claim 80, wherein the ETBR antagonist and the immune checkpoint inhibitor are administered at different times.

### Claim 88 (depends on 87)

The method of claim 87, wherein the ETBR antagonist is administered at least 2 times before each administration of the immune checkpoint inhibitor.

### Claim 89 (depends on 87)

The method of claim 87, wherein the ETBR antagonist is administered 3 times about every 21 days and the immune checkpoint inhibitor is administered 1 time about every 21 days.

### Claim 90 (depends on 71)

The method of claim 71, wherein the subject is a human subject.
